Entest Group Inc

[72chevnj]

NEWS!!! For Wed 21!!

Entest BioMedical Excited With Progress on 10 Dog Pilot Study of "Universal Donor" Stem Cell Treatment for Canine
* Reuters is not responsible for the content in this press release.
Wed Mar 21, 2012 8:30am EDT
SAN DIEGO, CA, Mar 21 (MARKET WIRE) --
Entest BioMedical Inc. (OTCQB: ENTB) (PINKSHEETS: ENTB)


-- Entest's McDonald Animal Hospital has treated 8 dogs in 10 Dog Pilot
Study.
-- All of which are showing positive results to the Stem Cell therapy.
-- Osteoarthritis impacts up to 30% of all dogs



Entest BioMedical Inc. (OTCQB: ENTB) (PINKSHEETS: ENTB) and
RenovoCyte LLC announced they have treated 8 canine patients of a 10 dog
pilot study utilizing Canine Endometrial Regenerative Cells (CERC)
licensed from Medistem Inc. (PINKSHEETS: MEDS) in the treatment of canine
osteoarthritis.

Previously, Entest announced the treatment of the first canine patient on
November 18, 2011. Since that time Entest's McDonald Animal Hospital has
treated 8 dogs in its 10 Dog Pilot Study with RenovoCyte. To date, all of
the dogs participating in this study have shown dramatic improvement in
their mobility and apparent reduction of pain.

Dr. Greg McDonald, Chief Veterinarian at McDonald Animal Hospital, said,
"50 million CERC stem cells have been injected intravenously into eight
dogs. Each dog selected for this study showed signs of arthritis.
Follow-up blood tests, urinalysis and physical exams are now being
scheduled for the patients that have already been treated. So far, all
these canine patients have shown improvement."

Entest BioMedical Chairman David Koos stated, "Osteoarthritis is
considered one of the most common causes of lameness in dogs, occurring
in up to 30% of all dogs. It is caused by a deterioration of joint
cartilage, followed by pain and loss of range of motion of the joint. We
expect this treatment to relieve these animals from the pain associated
with arthritis. This has extraordinary possibilities for dogs and may
lead the way for human treatment of arthritic pain."

The CERC is a "universal donor" stem cell product that does not require
matching with the recipient allowing for the generation of standardized
products that can be delivered to the office of the veterinarian ready
for injection. This is in stark contrast to current stem cell therapies
utilized in veterinary applications which require the extraction,
manipulation, and subsequent implantation of tissue from the animal being
treated. CERC is the canine equivalent of Medistem's Endometrial
Regenerative Cell (ERC). Medistem was recently granted approval from the
FDA to initiate a clinical trial in human patients using its ERCs.

"We are extremely pleased with our research relationship with Entest
BioMedical. This study of canine pets suffering from naturally occurring
osteoarthritis is a better test model than laboratory induced disease
because it will give us the opportunity for long term follow up of these
patients. RenovoCyte sees this study as part of the supporting
documentation that will be needed to obtain FDA approval for widespread
usage of this therapy," said Shelly Zacharias, DVM, Director of
Veterinary Operations, RenovoCyte, LLC.

A spokesperson for Entest noted the Company is also currently conducting
a 10 dog safety study on its immune-therapeutic cancer vaccine for dogs,
having treated 3 dogs so far.

About Entest BioMedical Inc.:
Entest BioMedical Inc.
(http://www.entestbio.com) is a veterinary biotechnology company focused
on developing therapies that harness the animal's own reparative /
immunological mechanisms. The Company's products include an
immuno-therapeutic cancer vaccine for canines (ImenVax(TM)). ImenVax(TM)
is less invasive and less traumatic in treating cancer. Additionally, the
Company serves as the contract research organization conducting a pilot
study on a stem cell based canine osteoarthritis treatment (developed by
RenovoCyte LLC) utilizing a 'universal donor' stem cell. Entest is also
building a network of veterinary hospitals (with its initial location in
Santa Barbara, CA and anticipates acquiring other veterinary hospitals in
California) -- which serve as distribution channels for its products.


Disclaimer
This news release may contain forward-looking statements.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified. Future
events and actual results could differ materially from those set forth
in, contemplated by, or underlying the forward-looking statements. The
risks and uncertainties to which forward-looking statements are subject
include, but are not limited to, the effect of government regulation,
competition and other material risks.



Contact Information

Entest BioMedical Inc.

David R. Koos
Chairman & CEO

619.702.1404 Direct
619.330.2328 Fax
[e-mail]
www.EntestBio.com

found it here: http://www.reuters.com/article/2012/03/21/idUS128157+21-Mar-2012+MW20120321

Copyright 2012, Market Wire, All rights reserved.